Interferon-Β lipofection I. Increased efficacy of chemotherapeutic drugs on human tumor cells derived monolayers and spheroids

Cancer Gene Therapy

Volumn 19, Issue 7, 2012, Pages 508-516

  Villaverde, M S ^a   Gil Cardeza, M L ^a   Glikin, G C ^a   Finocchiaro, L M E ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

chemotherapy; Ewing sarcoma; interferon b; lipofection; melanoma; spheroids

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; LIPOSOME; METHOTREXATE; PACLITAXEL; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER MODEL; CANCER RESISTANCE; CELL POPULATION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; GENOTOXICITY; HUMAN; HUMAN CELL; IC 50; LIPOFECTION; LIPOSOMAL GENE DELIVERY SYSTEM; MELANOMA CELL; MONOLAYER CULTURE; PRIORITY JOURNAL; SARCOMA CELL; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR SPHEROID;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SHAPE; GENE TRANSFER TECHNIQUES; HUMANS; INTERFERON-BETA; LIPOSOMES; REACTIVE OXYGEN SPECIES;

EID: 84863727899     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.27     Document Type: Article

References (39)

1. Kurzrock R, Talpaz M, Gutterman JU. Hairy cell leukaemia: review of treatment. Br J Haematol 1991; 79: 17-20.
2. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198-1205. (Pubitemid 24058977)
3. Borden EC. Gene regulation and clinical roles for interferons in neoplastic diseases. Oncologist 1998; 3: 198-203. (Pubitemid 28307451)
4. Talpaz M. Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. Semin Hematol 2001; 38: 22-27. (Pubitemid 32816517)
5. Sherwin SA, Knost JA, Fein S, Abrams PG, Foon KA, Ochs JJ et al. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 1982; 248: 2461-2466. (Pubitemid 13233966)
6. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50: 3473-3486. (Pubitemid 20194083)
7. Daponte A, Ascierto PA, Gravina A, Lelucci MT, Palmieri G, Comella P et al. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group. Cancer 2000; 89: 2630-2636. (Pubitemid 32011608)
8. Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Brocker EB, Neumann C et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002; 86: 179-184. (Pubitemid 34185142)
9. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res 1996; 16: 759-764. (Pubitemid 26389112)
10. Finocchiaro LME, Villaverde MS, Gil Cardeza ML, Riveros MD, Glikin GC. Cytokineenhanced vaccine and interferon-b plus suicide gene as combined therapy for spontaneous canine sarcomas. Res Vet Sci 2011; 91: 230-234.
11. Matsumoto K, Kubo H, Murata H, Uhara H, Takata M, Shibata S et al. A pilot study of human interferon beta gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes. Jpn J Clin Oncol 2008; 38: 849-856.
12. Yoshida J, Mizuno M, Wakabayashi T. Interferon-b gene therapy for cancer: basic research to clinical application. Cancer Sci 2004; 95: 858-865. (Pubitemid 40045519)
13. Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 2006; 5: 3032-3041. (Pubitemid 46092044)
14. Shieh GS, Shiau AL, Yo YT, Lin PR, Chang CC, Tzai TS et al. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. Cancer Res 2006; 66: 9957-9966.
15. Deharvengt S, Rejiba S, Wack S, Aprahamian M, Hajri A. Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine. Int J Oncol 2007; 30: 1397-1406.
16. Abaza MS, Al-Saffar A, Al-Sawan S, Al-Attiyah R. c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumour Biol 2008; 29: 287-303.
17. Fandy TE, Shankar S, Srivastava RK. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAILresistant breast cancer cells. Mol Cancer 2008; 7: 60.
18. Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther 2010; 18: 1947-1959.
19. Finocchiaro LME, Bumaschny VF, Karara AL, Fiszman GL, Casais CC, Glikin GC. Herpes simplex virus thymidine kinase/ganciclovir system in multicellular tumor spheroids. Cancer Gene Ther 2004; 11: 333-345. (Pubitemid 38586089)
20. Gil Cardeza ML, Villaverde MS, Fiszman GL, Altamirano NA, Cwirenbaum RA, Glikin GC et al. Suicide gene therapy on spontaneous canine melanoma: correlations between in vivo tumors and their derived multicell spheroids in vitro. Gene Therapy 2010; 17: 26-36.
21. Sancëu J, Poupon MF, Delattre O, Sastre-Garau X, Wietzerbin J. Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Oncogene 2002; 21: 7700-7709. (Pubitemid 35398816)
22. Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 1998; 160: 328-333. (Pubitemid 28116746)
23. Finocchiaro LME, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Gene Therapy 2008; 15: 267-276. (Pubitemid 351223463)
24. Casais CC, Karara AL, Glikin GC, Finocchiaro LME. Effects of spatial configuration on tumor cells transgene expression. Gene Ther Mol Biol 2006; 10: 207-222. (Pubitemid 351976164)
25. Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994; 269: 2550-2561. (Pubitemid 24235749)
26. Gao X, Huang L. Cationic liposome-mediated gene transfer. Gene Therapy 1995; 2: 710-722. (Pubitemid 26043284)
27. Friedrich J, Eder W, Castaneda J, Doss M, Huber E, Ebner R et al. A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay. J Biomol Screen 2007; 12: 925-937. (Pubitemid 47548596)
28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
29. Li S, Wilkinson M, Xia X, David M, Xu L, Purkel-Sutton A et al. Induction of IFNregulated factors and antitumoral surveillance by transfected placebo plasmid DNA. Mol Ther 2005; 11: 112-119. (Pubitemid 40012005)
30. Boyd M, Mairs SC, Stevenson K, Livingstone A, Clark AM, Ross SC et al. Transfectant mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy. J Gene Med 2002; 4: 567-576. (Pubitemid 40268383)
31. Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud A, Sgouros G. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer 2004; 112: 713-721. (Pubitemid 39425955)
32. Huang G, Chen Y, Lu H, Cao X. Coupling mitochondrial respiratory chain to cell death: an essential role of mitochondrial complex I in the interferon-beta and retinoic acid-induced cancer cell death. Cell Death Differ 2007; 14: 327-337. (Pubitemid 46092235)
33. Kagan VE, Bayir HA, Belikova NA, Kapralov O, Tyurina YY, Tyurin VA et al. Cytochrome c/cardiolipin relations in mitochondria: a kiss of death. Free Radic Biol Med 2009; 46: 1439-1453.
34. Burger RM. Cleavage of nucleic acids by bleomycin. Chem Rev 1998; 98: 1153-1170.
35. Husain K, Whitworth C, Somani SM, Rybak LP. Carboplatin-induced oxidative stress in rat cochlea. Hearing Res 2001; 159: 14-22. (Pubitemid 32743314)
36. Kagan VE, Kuzmenko AI, Tyurina YY, Shvedova AA, Matsura T, Yalowich JC. Prooxidant and antioxidant mechanisms of etoposide in HL-60 cells. Cancer Res 2001; 61: 7777-7784. (Pubitemid 33049364)
37. Olszewska-Słonina DM, Styczyñ ski J, Czajkowski R, Drewa TA, Musiałkiewicz D. Cell cycle, melanin contents and apoptosis processes in B16 and Cloudman S91 mouse melanoma cells after exposure to cytostatic drugs. Acta Pol Pharm 2007; 64: 469-478. (Pubitemid 351360404)
38. Du ZX, Zhang HY, Meng X, Guan Y, Wang HQ. Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells. BMC Cancer 2009; 9: 56.
39. Villaverde MS, Gil-Cardeza ML, Glikin GC, Finocchiaro LME. Mechanisms involved in cell death and bystander effect induced by cationic lipid mediated interferon-b gene transfer to human tumor cells. Cancer Gene Ther 2012; 19: 420-430.